Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose oral dapsone plus intralesional meglumine antimoniate versus intralesional meglumine antimoniate alone for cutaneous leishmaniasis
IRCT20241028063523N3Phase 4Completed
- Sponsor
- PNS Shifa
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dapsone and meglumine antimoniate in cutaneous leishmaniasis (CL) (2 arms), sponsored by PNS Shifa. Primary endpoint: Complete response. Started Nov 2024; status: completed.
02
Drugs
dapsonemeglumine antimoniate
03
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on IRCT20241028063523N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20241028063523N3.